Stable spergualin analogues were synthesized by substitutions of the or-hydroxyglycine residue of spergualin with various a-or <y-amino acids.
1 ,5,10-triazadecane has possessed the strongest antitumor and immunosuppressive activities.
Spergualin, (-)-(156r)-l -amino-19-guanidinol l, 15-dihydroxy-4, 9, 12-triazanonadecane-10, 13-dione, is an antiturnor antibiotic isolated from culture filtrates of Bacillus laterosporus BMG-162-aF2.1 ' 2) Recently, the immunosuppressive activity of spergualin has been reported. 3) The total synthesis of spergualin has been accomplished. 43 The structure and antitumor activity relationships of spergualin analogues and derivatives against L1210 were also studied. Deoxyspergualin, the 15-deoxy analogue of spergualin, showed stronger antitumor5) and immunosuppressive6) activities than spergualin. This demonstrated that the 15-hydroxyl group was not essential for manifestation of these activities. These analogues, however, were unstable due to an unusual hemiaminal structure at 10~12 position in the molecule. Consequently they hydrolyzed gradually into an o>-guanidino-fatty acid amide and a hydrate of glyoxyloylspermidine in an aqueous solution as shown in Scheme 1.
In this paper, the syntheses and structure activity of stable spergualin analogues are reported in which the a-hydroxyglycine residue corresponding to 10~12 position of deoxyspergualin is substituted with various a-or w-aminoacids. Scheme1 . Degradation of spergualins in an aqueous solution.
glacial acetic acid treatment to yield 10-iV-phthaloyl-l ,5,10-triazadecane (VI) in a 38.5 %-yield from II. The two amino groups of VI were protected by benzyl or ter/-butoxycarbonyl (BOC) groups using benzyl-or tert-butyl 6t-4,6-dimethylpyrimidin-2-yl thiolcarbonate, respectively. Then the phthaloyl group was removed by hydrazine, and the obtained l,5-diprotected-l,5,10-triazadecane was coupled with protected amino acid 7V-hydroxysuccinimide ester (except benzyloxycarbonyl-DL-homoserine lactone in case of analogue 14) to yield 10-(iV-protected aminoacyl)-l ,5-diprotected-l ,5,10-triazadecane (VII). The amino acid protecting group in VII was selectively removed to give 10-aminoacyl-l,5-diprotected-l ,5,10-triazadecane (VIII), which was subjected to reaction with cy-guanidino-fatty acid iV-hydroxysuccinimide ester (IX) to give lO-tA^^-guanidino-fattyacy^aminoacyll-l^-diprotected-l jS, 10-triazadecane (X). Removal of two protecting groups from X by hydrogenolysis or acid treatment gave crude 10-[(JV-((y-guanidino-fattyacyl)aminoacyl]-l ,5,10-triazadecane (XI). Purification of the crude product was performed by column chromatography using CM-SephadexC-25 and Sephadex LH-20. The purity of the final compounds were confirmed to be over 99% by HPLCanalysis.
Structure Activity Studies Antitumor Activity against L1210 (IMC) Mouse Leukemia1}
In order to determine the antitumor activity of these synthesized analogues, the life span prolongation of L1210 (IMC) bearing mice treated with the analogues for 9 days starting the day after tumor innoculation was assessed.
The antitumor activity of the analogues is summarized in Tables 1 and 2 . The replacement of the a-hydroxyglycine moiety of deoxyspergualin (1) by amino acids was clearly successful. The analogues substituted with glycine (2), which is the 1 1-deoxy analogue of 1, exhibited remarkable activity but their effective dose range was slightly narrower than that of 1. Substitution by L-Ala (analogue 3), L-Leu (4), L-Phe (5), which are neutral amino acids, resulted in no activity. Analogues substituted with polar amino acids such as L-Asp(6), L-His (9), L-Arg (10) were also inactive.
Thus, the antitumor activity of the analogues substituted with <x-amino acids having polar groups and bulky groups in the side chain was dramatically decreased. While L-Ser has a larger side chain than L-Ala, the analogue ll expressed unexpectedly significant antitumor activity.
L-Ser is considered to be the one methylene unit-inserted analogue of a-hydroxyglycine, so analogues with two more methylenes (analogues 13 and 14) were synthesized, however they were inactive. Considering this, a hydrogen, hydroxyl or a hydroxymethyl group at position ll in the molecular structure seems to be very important for the exhibition of strong antitumor activity.
WhenD-Ser (12) was introduced in place of L-Ser to investigate the role of stereochemistry at position ll, this analogue showed no activity. Analogue 12 bearing D-Ser showed a (-j-)-value for specific rotation, however, analogue ll having L-Ser, 1 and spergualin,70 which expressed strong activity, had a (-)-value. This result agrees well with the observation of Umedaet al.8) Because of difficulties in directly determining the absolute configuration of spergualin and 1, our result was considered to be an alternative proof that an^-configuration of the stereochemistry of position 1 1 in these analogues is required for antitumor activity.
Amonganalogues replaced with cy-amino acids, the /3-Ala analogue (15) showed no activity, while f-aminobutyric acid (?--Aba, 16) exhibited moderate antitumor activity. An analogue substituted with a-hydroxy-^-aminobutyric acid (HABA,17), which is the a-hydroxy analogue of 16, showed stronger antitumor activity than 16.
Umeda et alP reported that l-amino-21-guanidmo-ll-hydroxy-4,9,12-triazauneicosane-10,13-dione, having two more methylene groups in the guanidino-fatty acid residue than 1, showed a strong activity similar to 1. Therefore, an analogue 18 with two more methylene groups than analogue ll 1 633 was synthesized and tested for antitumor activity. As expected, analogue 18 revealed almost the same activity as analogues 2 and ll. Although, analogues 16 and 17 have two more methylene groups than analogue 2, but not in the guanidino-fatty acid residue, these analogues, especially analogue 17, had significant antitumor activity.
These results indicate that not guanidino-fattyacyl but the guanidino-fattyacylaminoacyl moiety is strictly limited in the molecular length required to exhibit activity. Analogue 17 has a hydroxyl group at the 1 1 position in the molecule and exhibited a moderate antitumor activity. Thus, the importance of the hydroxyl group at this position was confirmed once again. From these results, it is concluded that the a-hydroxylglycine residue could be replaced with a glycine or serine residue.
In the following experiments, the straight chain (position 14~19) of the guanidinoheptanoic acid moiety was substituted with aralkyl groups to examine the role of the 7 straight methylenes in antitumor activity. As shown in Table 2 , three methylene units could be replaced with a benzene ring. Analogues 19 and 20, bearing a 4-guanidinophenylbutyric acid expressed stronger activity than 2 and ll.
Whenthe benzene ring was migrated on the butyryl skeleton, the activity level was significantly changed. 4-Guanidinopropylbenzoyl analogues (21 and 22) showed no activity. However, 4-guanidinomethylphenylpropionyl analogue (23) had slight activity. In addition, the introduction of a chlorine atom in the ring (27) and a change of the substituted position (24) resulted in the loss of activity. As mentioned above about the analogues having guanidinoheptanoic acid, analogues with two more methylenes demonstrate a strong activity. In contrast, 4-guanidinophenylpentanoic acid (25) and 4-guanidinophenylhexanoic acid (26) analogues showed little or no antitumor activity. This difference seems to indicate that the conformation of 25 or 26 differs from that of 2 or ll by introducing the benzene ring and the flexibility around the position 13^16 is indispensable for expression of the activity.
In conclusion, amongthe analogues so far synthesized, analogue 20 was the strongest in the antitumor activity.
Immunosuppressive Activity
Effects of the analogues on both cell-mediated (delayed type hypersensitivity, DTH9)) and humoral (antibody formation, PFC10)) were examined (Tables 1 and 2) .
Analogues 2, ll, 19 and 20, which had strong antitumor activity also showed the both immunosuppressive activities. Whereas 2 and ll exhibited almost the same DTHinhibitory activity as 1, they showed less PFC inhibition activity. Strong suppressions of both the DTHreaction and antibody formation were observed in 1, but analogues 2, ll, 19 and 20 were weaker in the suppression of antibody formation than suppression of DTH.
The analogues synthesized in this study could be classified into three categories. Group A (2, ll, 16, 17, 19 and 20) had both antitumor and DTH-suppressive activity, group B had neither activity and group C (25) showed weak antitumor activity and stronger suppression of the DTHreaction than PFC. It was interesting that analogue 25 suppressed the DTHreaction more than the antibody formation as shown in Table 2 .
The structure-activity relationships in the antitumor activity could be also applied to that of the immunological activities. This suggests that the mechanismof action of these compoundsfor these activities may be closely related. 2) 10-Pht-l,5-di-Z-l,5,10-triazadecane (V, R1=Z): IV (27.9 g, 80.0 mmol) was benzyloxycarbonylated using 43.9 g (160 mmol) of benzyl iS^^-dimethylpyrimidin^-ylthiolcarbonate and 17.8 g (176 mmol) of Et3N in 300 ml of CHC13.The reaction mixture was subjected to react for 6 hours at room temperature. The resulting solution was washed with 1 n HC1and satd NaCl aqueous solution and dried over anhydrous Na2SO4. Evaporation of CHC13gave 43. 3) l,5-Di-Z-l,5,10-triazadecane Dihydrochloride (VI, R^Z): V (Rx=Z, 31.3 g, 57.6 mmol) was treated overnight with 18.2 g (0.291 mol) of 80 % hydrazine hydrate in 600 ml of EtOH under reflux. The precipitates were removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was taken up by 300 ml of EtOAc, then VI was extracted with dil HC1. The aqueous layer was washed with EtOAc, then Na2CO3was added to bring the pH of the solution to 10. An oily deposit was extracted with 500 ml of EtOAc. The EtOAclayer was washed with satd NaCl aqueous solution, then dried over anhydrous Na2SO4. 7-Guanidinoheptanoic acid (1.87 g, 10 mmol)5) was dissolved in 1 n HC1, and the solution was con-centrated to dryness under reduced pressure to obtain 2.24 g of 7-guanidinoheptanoic acid hydrochloride. This was dissolved in 10 ml of DMF, and 2.06 g of dicyclohexylcarbodiimide (DCCD) and 1.00 g (12 mmol) of iV-hydroxysuccinimide (HOSu) were added to this solution under ice cooling. The solution was stirred for 30 minutes at 0°C, followed by standing at room temperature overnight. The solution was evaporated after filtrating the precipitates. Washing with petroleum ether and drying under reduced pressure of the resulting oily material gave 3.65 g of IX: *H NMR(DMSO-d6) <H.l -2.0 (8H, br), 2.67 (2H, t, J=6 Hz), 2.84 (4H, s), 3.1 (2H, m), 7.3 (1H, br), 8.0 (4H, br) .
7) 10-[iV-(7-Guanidinoheptanoyl)-Gly]-l,5-di-Z-l ,5,10-triazadecane Hydrochloride (X, R^Z, X=Gly, Y=(CH2)6) : VIII (12.5 g, 24 mmol), 1 1.3 g of 7-guanidinoheptanoic acid iV-hydroxysuccinimide ester hydrochloride (IX) and 4.0 ml (29 mmol) of Et3N was dissolved in 120 ml of THF and 50 ml of DMF.The resulting solution was stirred overnight at room temperature. Concentration of the reaction mixture gave an oily residue, which was taken up with 700 ml of EtOAc. The EtOAc layer was washed with 0.5 n HC1 saturated with NaCl and satd NaCl aqueous solution. An oily material which precipitated during these washings was dissolved by addition of a small amount of EtOH. Then the EtOAc layer was dried over anhydrous Na2SO4. The filtrate was evaporated to obtain 20. 8) 10-[iV-(7-Guanidinoheptanoyl)-Gly]-l,5,10-triazadecane Trihydrochloride (XI, X = Gly, Y=(CH2)6) (Analogue 2): X (20.8 g, 24 mmol) was dissolved in.300 ml of MeOHand 10 ml of AcOH, and hydrogenated over 0.5 g of palladium black for 3 hours at room temperature. The filtrate was concentrated under reduced pressure, which was dissolved in 70 ml of water. The solution was passed through a column packed with 1,500 ml of CM-Sephadex C-25 (Na+). Active fractions were collected by eluting the column in the mode of gradient between 7,500 ml of water and 7,500 ml of 1 n NaCl solution. After the collected fractions were concentrated to dryness, MeOHwas added to the residue, and insoluble materials were filtered off. In order to remove the small amount of NaCl, the resulting oily material was dissolved in 50 ml of MeOH. The solution was chromatographed on a column packed with 400 ml of Sephadex LH-20 to obtain 5.30 g of XI. Lyophilization gave purified analogue 2 in The reaction mixture was concentrated to give an oil, which was dissolved in 200 ml of EtOAc. The EtOAc layer was washed with 5 % NaHCO3 aqueous solution and water, then dried over anhydrous Na2SO4 03 mmol) and 6.14 g (7 mmol) of 7-guanidinoheptanoic acid />-nitrophenyl ester were treated in a similar manner NOV. 1988 as the preparation of X (RX =Z, X-Gly, Y=(CH2)6) to give 4.77 g of 10-[iV- Procedures similar to that used for analogue ll were followed in the preparations of analogues acid iV-hydroxysuccinimide ester hydrochloride were treated in a mixed solvent of 5 ml of THF and 8 ml of DMFat room temperature overnight. The reaction mixture was evaporated and the resulting oily material was dissolved in 50 ml of 2 % aqueous solution of H3PO4and the solution was washed with EtOAc. Na2CO3was added to the solution to adjust the pH to 10.5. Then the aqueous layer was extracted with two 50-ml portions of EtOAc and AcOHwas added to the EtOAc solution until it became substantially neutral. Concentrating the mixture under reduced pressure gave 1.08 g of oily 10-[7V- (7- : 4-(4-Guanidinophenyl)butyric acid hydrochloride 1.56 g (6.05 mmol) was dissolved in DMF(20 ml). To the solution was added HOSu0.84 g (7.26 mmol) and DCCD1.50 g (7.26 mmol) under ice cooling and the solution was reacted overnight. The precipitates were filtered off and the filtrate was added to the solution of 10-glycyl-l,5-di-Z-l,5,10-triazadecane 2.59 g (5.5 mmol) and Et3N 0.61 g (6.05 mmol) in DMF(30ml). The mixture was stirred overnight at room temperature then evaporated to give an oily material. This was dissolved in EtOAc (300 ml) and EtOH (60 ml), and the solution was washed with 5% H3PO4, 5% Na2CO3and satd NaCl solution, successively. The solution was dried over anhydrous Na2SO4and the filtrate was concentrated under reduced pressure to give 3.3 g of pale yellow oil in a yield of89. 
,5-di-Z-l ,5,10-triazadecane 3.3 g (4.90 mmol) was hydrogenated over palladium black in 40 ml of AcOHfor 10 hours at 50°C. The filtrates was evaporated to yield 2.10 g of oily material. This was dissolved in 10 ml of H2Oand the solution was passed through a column packed with 220 ml of CM-Sephadex C-25 (Na+). The adsorbent was eluted in a mode of gradient between 1,100 ml of distilled H2O and 1,100 ml of 1.0 m NaCl solution. The fractions containing the title compoundwere collected and evaporated to dryness. To this residue was added MeOHto remove insoluble materials by filtration. The filtrate was purified in the same manner as described for analogue : Methyl 3 -(4-acetylaminomethylphenyl)-propionate 5.0 g (21.25 mmol) was added to a sulfuryl chloride (85 ml) solution of anhydrous aluminum chloride 14.2 g (106 mmol) at -25°C. Thereafter, the temperature of the mixture was gradually elevated to 5°C, then the reaction mixture was subjected to react for 24 hours. It was poured onto crushed ice. The resulting solid material was extracted with CHC13(1,000 ml). It was washed with 5% Na2CO3, 5% H3PO4and water and dried over anhydrous MgSO4.The filtrates was dried up and residual oily product was subjected to a column chromatography of silica gel (300 g). Eluting with a mixture of toluene and EtOAc (1 : 1), the fractions with desired product was collected and evaporated to dryness to provide 1.93 g of the title compound in a yield of 33.7%: MP 91-93°C; *H NMR(400 MHz, CDC13) 8 2.03 (3H, s), 2.63 (2H, t, /=7.7 Hz), 3.04 (2H, t, /=7. 
